Lipton RB, et al. Patient Global Impression of Change related to improvement in most bothersome symptom following treatment with eptinezumab. IHC-PO-167. IHC 2019, 5-8 sept. Dublin, Ierland.
Extra voordeel langere dosisinterval natalizumab: minder JCV-conversie
mei 2025 | Multipele Sclerose